Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...

Google is rolling out a multimodal option under Search Console's Web search type. It covers searches that use an image, including Lens and Circle to Search. It shows which pages image-based searches ...

Here is a screenshot of what I mean - as you can see, when you mouse over a URL in the Google Search results, you can see Google is using a goto URL parameter to take you to the site, as opposed to ...

But a new study shows that work use cases make up less of the picture than AI companies claim. AI companies like Anthropic and OpenAI regularly publish reports on how people are using products like ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

Hamlin has been in the tech field for over nine years. Since 2017, his work has appeared on MakeUseOf, Android Police, OSXDaily, Beebom, and more. He served as the Senior Editor at Valnet's MakeUseOf ...